25-Hydroxyvitamin D and metabolic-related laboratory values in women with schizophrenia and hyperprolactinemia

J Psychiatr Res. 2022 Jul:151:25-29. doi: 10.1016/j.jpsychires.2022.03.046. Epub 2022 Apr 8.

Abstract

Schizophrenia is a severe mental disorder with various medical comorbidities and early mortality. Hyperprolactinemia is common in women and its impact on sexual function, galactorrhea and amenorrhea is well known. This paper evaluates the risk of 25-hydroxy vitamin D deficiency and other metabolic related laboratory abnormalities in women with schizophrenia having hyperprolactinemia (N = 43). The mean prolactin level in these women was 88.5 ± 56.0 ng/mL. We found that 100% of women were overweight of which 74% (32/43) of the women were obese, 56% (23/41) had abnormal total cholesterol levels and 30% (13/43) had high fasting blood glucose. Vitamin D levels were considered deficient or inadequate in 37% of women. We did not see significant correlations of prolactin with laboratory measures, however all female patients had elevated and high prolactin levels, leading to low variability in a small sample, which may have precluded seeing any direct relationships. Recognizing prolactin related side effects and understanding the role of other health measures seen in women with antipsychotic induced hyperprolactinemia in our female patients are critical steps toward better personalization of their care and recovery.

Keywords: 25-hydroxy vitamin D; Body mass index; Cholesterol; Schizophrenia; Women.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Female
  • Humans
  • Hyperprolactinemia* / drug therapy
  • Pregnancy
  • Prolactin
  • Schizophrenia*
  • Vitamin D / analogs & derivatives

Substances

  • Antipsychotic Agents
  • Vitamin D
  • Prolactin
  • 25-hydroxyvitamin D